Dermira, Inc.
275 Middlefield Road
Suite 150
Menlo Park
California
94025
United States
Tel: (650) 421-7200
Fax: 650-365-3410
Website: http://www.dermira.com/
Email: info@dermira.com
112 articles about Dermira, Inc.
-
Dermira Announces Proposed Public Offering Of Common Stock
3/1/2017
-
Dermira Data From DRM04 And Olumacostat Glasaretil Clinical Programs To Be Presented At American Academy of Dermatology Annual Meeting
2/28/2017
-
Dermira To Report Fourth Quarter And Full Year 2016 Financial Results
2/23/2017
-
Dermira, UCB Group Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing
1/19/2017
-
Dermira Provides Corporate Update
1/6/2017
-
Lori Lyons-Williams Joins Dermira As Chief Commercial Officer
1/5/2017
-
Dermira Elects Emmanuel Caeymaex To Board Of Directors
1/5/2017
-
Dermira Initiates Phase III Clinical Program In Acne
1/3/2017
-
Dermira Release: Second CIMZIA (Certolizumab Pegol) Phase III Trial Meets Co-Primary Efficacy Endpoints In Patients With Moderate-To-Severe Chronic Plaque Psoriasis
12/8/2016
-
Dermira Presents Data From DRM01 Phase IIb Clinical Program At Annual Meeting For Dermatologists
10/21/2016
-
Dermira To Present Data From DRM01 And DRM04 Clinical Programs At Fall Clinical Dermatology Conference
10/13/2016
-
Bay Area Dermira's CImzia Meets Co-Primary Endpoints in Key Phase III Study
10/3/2016
-
Dermira To Present Data From DRM04 Phase III Clinical Trials At Late-Breaking News Session At European Academy Of Dermatology And Venereology Congress
9/28/2016
-
Dermira Licenses DRM04 To Maruho For Hyperhidrosis In Japan
9/21/2016
-
Bay Area's Dermira Snags Deal to License Rights to Three of Takeda's Early-Stage Programs
9/12/2016
-
Dermira Reports Second Quarter 2016 Financial Results And Provides Corporate Update
8/9/2016
-
Dermira Jumps as Excessive Armpit Sweating Drug Succeeds in Late-Stage Studies
6/2/2016
-
Dermira Completes Patient Enrollment For Second CIMZIA (Certolizumab Pegol) Phase III Clinical Trial In Psoriasis Program
11/19/2015
-
Dermira Reports Third Quarter 2015 Financial Results And Provides Corporate Update
11/11/2015
-
Dermira Completes Patient Enrollment For First CIMZIA (Certolizumab Pegol) Phase III Clinical Trial In Psoriasis Program
10/13/2015